Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Junying Yuan
Harvard Medical School, Department: Anatomy/cell Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Denali
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Denali recently became a public company. Dr. Yuan's equity is currently locked. Once the stock converts we update this report with the updated and accurate value.
The research in this grant looks at the involvement of the enzyme RIPK1 in the pathogenesis of Alzheimer's disease. Expiraments will involve inhibition of RIPK1 by Nec-1s, a family of RIPK1 inhibitors that were developed in the Yuan lab. The research proposal states that Denali has one of the Nec-1s analogs developed in the Yuan lab Phase 1 clinical trials targeting Alzheimer's and ALS.
Investigating the role and mechanism of RIPK1 in mediating cerebrovascular pathology of AD
While amyloid pathology has been recognized as a hallmark of AD, there is an increasing appreciation of the contribution from cerebrovascular pathology to AD. However, the mechanism that mediates the cerebrovascular dysfunction in AD is unclear, and most importantly, we have scarce knowledge regarding druggable targets that can be safely targeted to remedy the cerebrovascular impairment for the treatment of AD. This study will provide new insights into the mechanisms by which RIPK1 mediated inflammation and necroptosis contributes to the cerebrovascular pathology in AD as well as important biomarkers for the human clinical trial on RIPK1 inhibitor targeting AD.
Filed on April 23, 2018.
Tell us what you know about Junying Yuan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.